Background
==========

One of the results from genome sequencing projects, such as the human genome project, is to promote the development of structural genomics/proteomics endeavors which focus on the large-scale determination of protein structures and functions. The traditional cloning and expression approach is inadequate for such a daunting task, and high throughput (HTP) methods are clearly necessary \[[@B1],[@B2]\]. An integrated robotic pipeline can streamline the complex experimental procedures and makes it possible to carry out gene cloning and protein expression for a large amount of targets in a timely and reproducible manner. Some groups have developed the HTP cloning method including the design of nested primers for PCR cloning \[[@B3]\], while we have also developed an automated pipeline for recombinant protein expression, applying the GATEWAY cloning/expression technology and a stepwise automation strategy on an integrated robotic platform \[[@B4]\]. The robotic pipeline is fully operational and has produced a large number of soluble recombinant proteins in *E. coli*using the open reading frame cDNA library (ORFeome) for *C. elegans*and human genomes \[[@B5],[@B6]\].

However, the success rate of expressing soluble proteins is limited when the full length ORF was used to express the target protein. In a number of cases, including our own results, soluble proteins could be expressed in *E. coli*when a smaller fragment derived from the ORF was used for expression \[[@B7]-[@B10]\]. We have identified smaller protein fragments from spontaneous degradation and limited proteolysis, and recloned them for expression \[[@B7],[@B8]\]. Compared to expressing soluble proteins carrying GATEWAY tags due to cloning artifacts, the soluble expression rate was increased from 1.3% to 27.6% when the GATEWAY tags were not included, and a 41.7% rate of soluble expression was achieved when the identified fragment without both GATEWAY tag encoded sequences was recloned (data not shown). The GATEWAY tags named here refer to the amino acid sequences TSLYKKAGX and TQLSCTKW, resulted from the recombination site attB1 or attB2, respectively, generated by the GAETWAY LR reaction \[[@B11]\]. X refers to the amino acid that depends on the coding sequence. With pET15g as the expression vector, which was engineered using pET15b (Novagen) to be compatible with GATEWAY cloning \[[@B4]\], the final N-terminal tag sequences in the originally and newly cloned genes are MGSSHHHHHHSSG[LVPRGS]{.ul}QS*TSLYKKAGX*and MGSSHHHHHHSSG[LVPRGS]{.ul}QS*TSLYKKAG*LVPRGS respectively, in which HHHHHH is the his-tag followed by a thrombin cleavage site ([LVPR\|GS]{.ul}, named thrombin site I, the cutting site is between R and G) deprived from pET15b vector, *TSLYKKAG*is the N-terminal GATEWAY tag generated by GATEWAY LR reaction, and the last LVPRGS is the newly introduced thrombin site (named thrombin site II) that is used to eliminate the N-terminal GATEWAY tag. No C-terminal GATEWAY tag was present in the newly cloned genes by the introduction of a stop codon after the coding sequence. Thus the clones in which GATEWAY tags were included expressed a recombinant protein that had Sequence I, i.e. GSQSTSLYKKAGX at the N-terminus and Sequence II, i.e. TQLSCTKW at the C-terminus in addition to the coding sequence after the his-tag was removed by protease digestion through the thrombin site I. In the clones without the GATEWAY tags, the recombinant protein contained only GS at the N-terminus in addition to the coding sequence. More recently, 23 fragments were recloned and 6 of them have resulted in diffracting quality crystals, which led to 3 structures \[[@B7],[@B8]\]. These findings suggested that the sequences derived from GATEWAY tags affect the soluble expression and a well folded fragment/domain of the target protein is best suited for expression of a soluble recombinant protein in *E. coli*. In fact, 90% of the structures of human proteins deposited in the Protein Data Bank (PDB) \[[@B12]\] comprise a fragment of the gene. We therefore modified our robotic pipeline to incorporate an automatic operation that can select a proper domain/fragment from the ORF for recombinant protein expression and used new cloning strategy described above.

New bioinformatics tools and cloning methods were developed and adopted to the previously established robotic pipeline, as discussed in this report. The major modifications included the automatic design of PCR primers, and improved multi-step laddered PCR, followed by previously established micro BP reaction of GATEWAY cloning, transformation, plating of transformed *E. coli*cells (DH5α), colony picking and entry clone plasmid DNA extraction. The automated cloning module is combined with our automated protein expression module that consists of construction of expression clones in 96-well plates, protein solubility profiling by dynamic ELISA, as a protein expression platform for structural genomics/proteomics. The cloning module is flexible and efficient to carry out different cloning strategies as shown here.

A number of algorithms for predicting domain boundaries have been developed previously \[[@B13]-[@B18]\]. Most of them, however, are not publicly available or cannot be adapted to our HTP pipeline. We report here a new composite scheme to locate domains with relatively accurate boundaries. Programs included in the scheme are InterPro/InterProScan \[[@B19],[@B20]\] and Domain Linker Finder \[[@B16]\], BLAST \[[@B21]\], SignalP \[[@B22],[@B23]\] and TMHMM \[[@B24]\]. The BLAST alignment and signal peptide, transmembrane (TM) region prediction were combined with the results of InterPro/InterProScan and Domain Linker Finder to define the fragment for cloning. This composite method has been validated with experimental results.

Results and discussion
======================

HTP cloning of 366 ORFs
-----------------------

The GATEWAY system is a suitable method for HTP cloning in 96-well plates. However, when entry clones (generated with pDONR201) and the expression vector pET15g are combined by the LR reaction, the recombination sequence attB1 may add additional unwanted 9 amino acids (TSLYKKAGX) at the N-terminus if the insert is downstream from a fusion peptide, and the attB2 site may add TQLSCTKW at the C-terminus if no stop codon follows the coding sequence. We named sequences from attB1 and attB2 as the GATEWAY tags. The additional amino acids derived from GATEWAY tags may interfere with subsequent experiments, such as soluble expression of the recombinant protein, purification problems due to aggregation of the protein, and crystallization of the protein (see descriptions in Background). It is therefore desirable to engineer a protease (thrombin here) cleavage site (PCS) after attB1 (Figure [1](#F1){ref-type="fig"}). A stop codon was also added right after the coding sequence in primer design to eliminate the extra amino acids at the C-terminus due to GATEWAY cloning. After the protein is purified, all amino acids prior to PCS, i.e. MGSSHHHHHHSSGLVPRGSQSTSLYKKAGLVPR, can be removed by the protease cleavage. Compared with the clones in which GATEWAY tags were included, newly cloned and expressed recombinant proteins contained only GS at the N-terminus in addition to the coding sequence. And if no new PCS was introduced, expressed proteins would have Sequence I, i.e. GSQSTSLYKKAGX at the N-terminus and Sequence II, i.e. TQLSCTKW at the C-terminus in addition to the coding sequence after the his-tag was removed by protease digestion through the thrombin site I (For details, see Background). Since the PCS was included in the primer synthesis in our strategy and the long forward primer would be costly and could increase the chance of errors, we designed a PCR strategy using two forward primers and two reverse primers (see Methods: Primer design and the PCR protocol for HTP cloning). This strategy has two advantages: only short primers are required, and primer F2, R2 could be synthesized in bulk. Such measures significantly reduce the cost and the error rate in 96-well operations.

A comprehensive computer program has been developed to carry out primer designs for selected genes. Usually the length of the gene-specific nucleotides in the entire primer should be maintained between 20 to 30 bases according to the manufacturer\'s manual \[[@B25]\] and our previous experience. The length of gene-specific oligos in this program is therefore set in this range. Since PCR clones are to be carried out in 96-well plates, conditions for all wells, such as denaturation time, cycle number, are the same even though each well represents a different gene. Therefore in addition to grouping coding regions with a similar length in one plate, we also chose to design primers that would result in a similar melting temperature (Tm). The best value for Tm was about 60°C for our experiments, so we tried to make the Tm of all oligos as close to 60°C as possible by adding or subtracting one base at a time. Besides the length of oligos, the salt concentration can also affect the Tm. In our program, the salt concentration was set at 10 mM. After the gene-specific oligo was designed with optimal Tm, sequences corresponding to attB1 or attB2, PCS and a stop codon were added. The primer design program was written in PERL, which could be easily modified to accommodate changes in primer sequences.

![**The primer design strategy using two pairs of primers**. Primer F2 and R2 contained attB sites and no gene specific region, which could be synthesized in bulk; Primer F1 and R1 contained gene specific sequences and an overlap region with Primer F2 and R2. CDS stands for coding sequence and a protease cleavage site was engineered after attB1 site.](1472-6750-7-45-1){#F1}

After receiving primers for 90 *C. elegans*, 88 Brucella, and 188 human ORFs in 96-well plate, HTP cloning (Figure [3](#F3){ref-type="fig"}), including PCR, E-Gel check, BP reaction, transformation, colony picking, cell culture and mini-prep, was performed on our integrated robotic platform. From 366 attempted amplifications, 337 PCR products could be detected by E-Gel (Figure [4](#F4){ref-type="fig"}). Interestingly, 20 vectors, out of 29, whose PCR products could not be detected by E-Gel could still be transformed and obtained as entry clones successfully. This phenomenon has also been observed by other research groups \[[@B26]\]. Including clones that were derived from PCR products not detectable by E-Gel, but transformed successfully, our PCR protocol showed a success rate of 97.5%. Our follow-up results suggested that PCR determines the final success rate of the whole HTP cloning process (Table [1](#T1){ref-type="table"}), whereas other steps, such as BP reaction, transformation, have negligible effects on the final outcome. Finally 96.7% ORFs were obtained as entry clones, which were verified by PCR/E-Gel check.

![**A schematic representation of HTP cloning and expression pipeline with the aid of bioinformatics tools**. In above HTP cloning pipeline, some steps, which were marked with star, were not performed on BiomekFX robot. ExtractCDS and BatchPrimer were two PERL programs used for extraction of the DNA coding sequence from a full-length sequence (ORF) and design of gene specific primers.](1472-6750-7-45-3){#F3}

![**An E-Gel test result for entry clones of the second plate of 94 human genes**. 2% E-Gel^®^96 Agarose with E-Gel^®^Low Range Quantitative DNA Ladder were used in the test.](1472-6750-7-45-4){#F4}

###### 

Statistic of PCR and entry clone success rates of HTP cloning

                 all   PCR (success rate)   entry clone (success rate)
  -------------- ----- -------------------- ----------------------------
  *C. elegans*   90    85 (94.4%)           83 (92.2%)
  Human          188   184 (97.9%)          183 (97.3%)
  Brucella       88    88 (100%)            88 (100%)
  Total          366   357 (97.5%)          354 (96.7%)

Validation of domain identification
-----------------------------------

Proteins are usually composed of multiple domains connected by linkers. Removal of flexible tails or separation of fragments would yield more compact and stable protein fragments that are more suitable for expression of a soluble recombinant protein and subsequent studies including crystallization, as demonstrated by data presented below. We aimed at developing an integrated strategy, named DDBP (domain/domain boundary prediction), to predict domain boundaries and stable fragments within the full length protein coded by the ORF. In this strategy, InterPro/InterProScan, PDB homology alignment, and Domain Linker Finder were the core methods used for domain prediction. In addition, signal peptide prediction by SignalP and TM regions prediction by TMHMM provided supplementary information for more accurate prediction.

InterPro is an integrated database that consists of most of the essential databases for domain and function site available today, such as PFAM \[[@B27]\], ProDom \[[@B28]\], SMART \[[@B29]\], PRINTS \[[@B30]\], PROSITE \[[@B31]\], TIGRFAM \[[@B32]\], SUPERFAMILY \[[@B33]\], etc. InterProScan, which is used together with InterPro database, is a tool that combines different protein signature recognition methods into one resource. Since InterPro contains many different domain and function site databases, conflicted results often appear when different databases were used. Moreover, InterPro/InterProScan analysis could only predict the core region of a domain, but not the domain boundaries. To improve the prediction accuracy, Domain Linker Finder (DLF), which applies the neural network method to distinguish domain linker sequences from non-linker sequences, was used to confirm domain prediction results obtained by InterPro/InterProScan, and to define more accurately the domain boundaries.

As the first step of DDBP, prediction of the signal peptide and the TM region for each ORF was carried out by SignalP and TMHMM, respectively. The identified signal peptide was eliminated as an unstable region, and TM regions would be treated as domain linkers that were later integrated into the results from DLF. The second step is to perform BLAST analysis against the PDB database to find potential domain relevant information. Finally InterPro/InterProScan and DLF programs were executed.

When results of InterPro/InterProScan and DLF were available, further analyses were performed: (1) if results of InterPro/InterProScan can be confirmed by PDB alignment results, manually integrate them and decide common domain boundary positions. For example, protein 3-H6, i.e. NP_508026 (Figure [5A](#F5){ref-type="fig"}), which comprises 431 amino acids, has no signal peptide and TM regions according to the prediction of SignalP and TMHMM. The result of InterPro/InterProScan showed this protein contains three possible domains/fragments: Domain1 (24--118), Domain2 (141--234) and Domain3 (254--370). While PDB alignment results showed: (a) the region 4--131 of 3-H6 is homologous to the region 20--147 of a 149-Amino-acid protein (PDB ID: 1ROU, containing 1 domain) with 60% identity; (b) the region 4--244 of 3-H6 is similar to the region 41--280 of a 280-amino-acid protein (PDB ID: 1Q1C, containing 2 domains) with 48% identity; (c) the region 7--408 of 3-H6 is similar to the region 24--422 of a 457-amino-acid protein (PDB ID: 1KTO/A, containing 3 domains) with 40% identity; (d) the region 128--428 of 3-H6 is similar to the region 22--330 of a 336-amino-acid protein (PDB ID: 1P5Q/A, containing 2 domains) with 35% identity. The results from InterPro/InterProScan prediction appear to be consistent with the results of PDB alignments. By combining these two results, three protein fragments were selected for 3-H6: 1--131, 128--244, and 245--431 as the stable region. (2) if results of InterPro/InterProScan and PDB alignments were not consistent, but one of two results could be confirmed by DLF, the consistent results were manually combined and domain boundary positions were assigned. TM regions were integrated with the result from DLF at this stage as well. For example, 11020-H6, i.e. the region 299--792 of NP_493412 (Figure [5B](#F5){ref-type="fig"}), a 494-amino-acid protein without TM regions and a signal peptide, was predicted to have three possible domains/fragments by InterPro/InterProScan (Fragment1: 53--225; Fragment2: 236--494; Fragment3: 337--475) and no homologous protein structures were found by PDB alignment. DLF results showed that protein 11020-H6 may contain five possible domain linkers (DL1: 19--52; DL2: 106--145; DL3: 215--241; DL4: 325--330; DL5, 373--383), in which DL1 and DL3 were consistent with Fragment1, the N-terminal end of Fragment2; and DL4 was consistent with the N-terminal end of Fragment3. DL2 was ignored. Since Fragment3 was contained within Fragment2, it is possible that Fragment2 might contain at least two domains, and Fragment3 might be one of them. The final predicted stable domains/fragments of 11020-H6 were: 53--225, 236--494 and 331--494; (3) if results of InterPro/InterProScan and PDB alignments were not consistent, and no result from DLF was available or the DLF prediction didn\'t support any results from InterPro/InterProScan or PDB alignments, the N-terminus and C-terminus of the ORF would be treated as domain boundaries. After completing the prediction, a final check was performed to ensure that the region between two predicted domain boundaries should be at least 80 amino acids. If a predicted domain contained less than 80 amino acids, one of the two domain boundaries with a less reliability would be omitted and the domain was joined to the next domain/fragment, except that positive PDB alignment results were available and supported that the short predicted domain was long enough to form a stable domain.

![**Two examples for interpreting DDBP (domain/domain boundary prediction) method**. **A:**According to the prediction of Interpro/InterProScan, 3-H6 (NP_508026), a 431-amino-acid protein that has no TM region or the signal peptide, possibly contained three domains: Domain1 (24--118), Domain 2 (141--234), and Domain 3 (254--370). a, b, c, d on the right of horizontal lines mark four separate alignment results between protein 3-H6 and Protein Data Bank (PDB) database. a: the region 4--131 of 3-H6 is homology with the region 20--147 of 1ROU with 60% identity; b: the region 4--244 of 3-H6 was similar to the region 41--280 of 1Q1C with 48% identity; c: the region 7--408 of 3-H6 was similar to the region 24-422 of a 1KTO/A with 40% identity; d: the region 128--428 of 3-H6 was similar to the region 22--330 of 1P5Q/A with 35% identity. By combining the results of Interpro/InterProScan and alignments, three protein fragments (1--131, 128--244, and 245--431) were selected for 3-H6 as stable domains/fragments. **B:**11020-H6 (corresponding to the region 299--792 of protein NP_493412), a 494-amino-acid protein that has no TM regions or the signal peptide, was predicted to have three possible domains/fragments (Fragment1: 53--225; Fragment2: 236--494; Fragment3: 337--475) by InterPro/InterProScan (shown on top). DLF results showed that protein 11020-H6 may contain five possible domain linkers (DL1: 19--52; DL2: 106--145; DL3: 215--241; DL4: 325--330; DL5, 373--383) (shown at the bottom). The stable domains/fragments of 11020-H6 were predicted as 53--225, 236--494 and 331--494 by the DDBP method (shown as the conclusion in the box at right).](1472-6750-7-45-5){#F5}

In order to validate this combination scheme, we constructed a dataset that contains the definition of 47 domains/fragments from our experimental results (see Method: Datasets for domain/domain boundaries prediction) and made a comparison between the experimental and DDBP prediction results (Table [2](#T2){ref-type="table"}). In the comparison, the experimentally determined domain/domain boundaries are assumed to be correct domain/domain boundaries. For a protein, whatever how many domains it contained or were predicted, if only two boundaries of one predicted domain were same with those of one correct domain, or its ranges \< = +10 aa, this prediction would be as an accurate prediction. Similarly, if 10 aa \< ranges \< = +30 aa, the prediction would be as a basically accurate prediction, and if range \> +30 aa, the prediction would be as a wrong prediction. For example, protein 11011-D8 (Table [2](#T2){ref-type="table"}) has one experimental determined domain: 45--190. With DDBP method, it was predicted with two possible domains: 1--107 or 52--190. Because one of predicted domains (52--190) was consistent with the correct result, i.e. ranges (52-45 = 7 and 190-190 = 0) \< = +10 aa, this prediction was as a accurate prediction. Protein 4-F5 (Table [2](#T2){ref-type="table"}) has one experimentally determined domain (1--144) and its predicted domains by DDBP method were 1--124 and 143--269. By comparison, 4-F5 was thought as a basically accurate prediction because its ranges (1-1 = 0 and 144-124 = 20) \< = +30 and \> +10 aa. The complete comparison for all 47 domains were listed in Table [2](#T2){ref-type="table"}, as showed that more than 60% of the prediction was consistent with experimental results, in which 43% was accurate (labeled with I in the column A) and 19% was basically accurate (labeled with II in the column A).

###### 

Comparisons between experimental and DDBP prediction results\*

  **A**                    **B**   **C**   **D**                  **E**                                                                                                         **F**                                                              **G**                                                                                                               **H**                                           **I**                          **J**          **K**
  --------- -------------- ------- ------- ---------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ------------------------------ -------------- ----------------------------------------------------------------------------
  **I**     11058-C7       249     no      no                     4--190; 1--220; 80--190                                                                                       no                                                                 24%, (7--240/8--268, 288); 26%, (4--240/7--225, 251)                                                                (1--249)\#                                      1--249                         NP_506406      F20G2.1
  **I**     11048-D3       199     no      no                     9--199                                                                                                        76--98, 181--181                                                   26%, (5--160/3--164, 208)                                                                                           (1--199)\$                                      1--199                         NP_502315      F35G2.2
  **I**     11011-D8       190     no      no                     8--36, 47--75, 83--111; 2--107;                                                                               148--172, 108--120, 82--92, 49--51                                 27%, (37--105/1--69, 146)                                                                                           (45--190)&                                      1--107, 52--190                NP_493641      F23F1.2
  **I**     18-A2          210     no      no                     29--79; 108--194                                                                                              no                                                                 30%, (75--193/4--115, 135)                                                                                          (74--210)&                                      75--210                        NP_491893      BAG1 (human) homolog family member (bag-1)
  **I**     11033-F3       208     no      no                     6--74; 128--194; 1--97; 80--207                                                                               39--56                                                             31%, (2--207/1--197, 198)                                                                                           (1--208)\#                                      1--208                         NP_496863      Glutathione S-Transferase family member (gst-16)
  **I**     11-D11         346     no      no                     80--317; 55--320; 219--317                                                                                    19--34, 116--126                                                   31%, (76--334/36--291, 298)                                                                                         (56--346)&                                      55--346                        NP_491872      C55B7.3
  **I**     11104-F4       370     no      no                     2--221, 1--370                                                                                                126--143, 348--352, 19--25, 71--82, 292--297, 233--237             34%, (128--347/15--231, 265)                                                                                        (125--370, 1--124)&                             1--125, 128--347               NP_001040820   Cell Division Cycle related family member (cdc-37)
  **I**     79-D4          401     no      no                     65--395; 37--400                                                                                              66--108, 27--45, 108--125, 217--236, 138--146                      35%, (212--395/2-- 185, 185)                                                                                        (206--401)\#                                    212--401                       NP_491735      C06A5.7b
  **I**     9-H3           212     no      no                     no                                                                                                            19--52, 162--192, 79--89                                           35%, (86--136/84-- 131, 217)                                                                                        (59--212)\$                                     53--212                        NP_493365      Y40B1B.5
  **I**     76-D4          254     no      no                     2--171; 3--250; 139--167                                                                                      139--147                                                           36%, (3--251/8--265, 278)                                                                                           (1--254)\#                                      1--254                         NP_001021765   Y47G6A.22
  **I**     8-C1           142     no      no                     4--140                                                                                                        no                                                                 46%, (5--141/9--149, 150)                                                                                           (1--142)&                                       1--142                         NP_499813      T12D8.6
  **I**     11-F6          327     no      209-- 231, 246-- 268   207--227, 246--266                                                                                            56--95, 19--56, 95--136, 136--161                                  50%, (141--167/1-- 28, 163)                                                                                         (1--182, 1--145)&                               1--135                         NP_491774      T09B4.5a
  **I**     1-F11          229     no      no                     148--217; 170--201; 170--212                                                                                  19--21, 129--134                                                   59%, (135--220/20--107, 113)                                                                                        (135--229)\#                                    135--229                       NP_506367      F53F4.3
  **I**     3-H6           431     no      no                     24--118, 141--234; 254--370; 261--370                                                                         397--413, 214--225, 100--107, 123--128                             60%, (4--131/20--147, 149); 48%, (4--244/41--280, 280); 40%, (7--408/24--422, 457); 35%, (128--428/22--330, 336);   (1--135)\#                                      1--131, 128--244, 245--431     NP_508026      FK506-Binding protein family member (fkb-6)
  **I**     20-H6          496     no      no                     38--496; 186--261, 293--363, 422--483; 183--272, 275--374, 422--487                                           120--151, 265--279                                                 66%, (394--496/1-- 103, 104) ; 75%, (183--269/1-- 87, 90); 75%, (290--366/1-- 78, 85)                               (169--385, 386--496)&                           183--272, 290--366, 394--496   NP_001022967   U2AF splicing factor family member (uaf-1)
  **I**     1-D10          206     1--21   no                     41--198; 23--77, 85--141, 143--196                                                                            no                                                                 no                                                                                                                  (23--206)\#                                     22--206                        NP_491320      R12E2.13
  **I**     11020-H6\*\*   494     no      no                     53--225; 337--475; 336--453; 236--494                                                                         19--52, 106--145, 215--241, 373--383, 325--330                     no                                                                                                                  (1--237, 238--494) &\$                          53--225, 236--494, 331--494    NP_493412      Y37H9A.3
  **I**     70-H8          130     no      107-- 129              109--129                                                                                                      19--104                                                            no                                                                                                                  (1--130)\#                                      1--130                         NP_491052      W03D8.3
  **I**     8-C9           183     no      no                     125--159;                                                                                                     no                                                                 no                                                                                                                  (1--183)\# ; (28--183, 23--183)\$               1--183                         NP_510277      BMP receptor Associated protein family member (bra-1)
  **I**     11005-B8       245     no      no                     no                                                                                                            19--20, 129--136, 41--46                                           no                                                                                                                  (9--245)\#                                      1--245                         NP_740981      R05F9.1b
  **II**    18-F7          288     no      no                     34--286                                                                                                       19--30, 72--78, 196--202, 66--70                                   45%, (35--286/21-- 274, 276)                                                                                        (32--266)\$                                     34--286                        NP_001021584   EXOnuclease family member (exo-3)
  **II**    4-F5           592     no      no                     189--269                                                                                                      485--509, 125--142, 19--37, 369--382,99--109, 311--317             35%, (210--269/15--74, 76);                                                                                         (1--144)&                                       1--124, 143--269               NP_494544      C16C8.16
  **II**    11011-C6       162     no      no                     4--162; 5--54, 71--132                                                                                        51--68                                                             no                                                                                                                  (1--148, 1--124)&                               1--162                         NP_500324      F42A6.6
  **II**    11058-H2       249     no      no                     4--190; 4--230; 4--209                                                                                        no                                                                 40%, (5--245/23-- 263, 267)                                                                                         (1--222)\$                                      1--249                         NP_506407      F20G2.2
  **II**    76-F10         263     no      no                     23--130; 33--109                                                                                              118--126, 20--20                                                   27%, (27--120/6--98, 108)                                                                                           (1--129)&                                       21--130                        T26031         hypothetical protein W01A8.2
  **II**    79-H11         245     no      no                     2--156, 1--241                                                                                                144--181, 181--204, 121--144                                       51%, (2--154/2--154, 155)                                                                                           (1--185)\$                                      1--156                         NP_492567      C03D6.5
  **II**    25--B11        302     no      no                     23--127; 45--114                                                                                              203--236, 19--24, 236--248, 146--161, 187--195                     no                                                                                                                  (1--153)&                                       23--145                        NP_492781      B0511.7
  **II**    11-D3          313     no      no                     28--214; 9--302                                                                                               151--174, 19--22                                                   no                                                                                                                  (1--313)\# ; (213--313)\$                       23--313                        NP_001021333   Suppressor of PResenilin defect family member (spr-2)
  **II**    11058-F12      272     no      no                     40--63; 40--68, 90--124                                                                                       no                                                                 32%, (67--119/3--54, 60); 26%, (40--119/5--84, 87); 31%, (41--114/36-- 113, 124)                                    (1--147)&                                       1--124                         NP_503566      F36F12.8
  **III**   20-D7          500     no      no                     311--395; 41--278; 283--436                                                                                   387--417, 288--308, 453--469, 481--482                             28%, (342--432/68--153, 289)                                                                                        (1--500)\# ; (298--500, 388--500, 407--500)\$   1--287, 283--452               NP_491868      lariat DeBRanching enzyme related family member (dbr-1)
  **III**   37-G9          245     no      no                     no                                                                                                            206--227, 19--21                                                   no                                                                                                                  (1--102, 103--245)&                             1--245                         NP_507040      F14H3.6
  **III**   70-D2          265     1--25   15--37                 69--243                                                                                                       223--247, 195--199                                                 22%, (128--264/13--121, 135)                                                                                        (1--130, 1--174)&                               1--265                         AAC25860       Hypothetical protein C37C3.3
  **III**   2-B6           316     no      no                     27--294                                                                                                       225--260, 174--191, 149--163, 296--298, 71--82, 84--84, 219--220   23%, (53--168/46-- 180, 201)                                                                                        (71--294)\# ; (104--316)\$&                     1--295                         NP_501422      D2096.8
  **III**   10-E5          274     no      no                     1--80, 108--190                                                                                               229--246, 193--213                                                 25%, (17--161/32-- 166, 196)                                                                                        (65--237, 1--74, 75--274)&                      1--192                         NP_502380      C25G4.6
  **III**   3-D2           419     no      no                     95--128, 133--166; 93--197; 133--166                                                                          196--217, 41--62, 259--275, 341--351, 19--21                       26%, (95--239/13-- 144, 166); 32%, (99--197/8--95, 118)                                                             (140--309, 290--419)&                           93--197, 93--258               NP_495087      C17G10.2
  **III**   113-H8         588     no      no                     232--342; 241--334                                                                                            492--515, 19--56, 81--132, 150--185                                29%, (234--328/2-- 85, 105)                                                                                         (1--345, 34--313)&                              232--342                       NP_740981      R05F9.1b
  **III**   76-F6          803     no      769-- 791              17--250, 558--652; 10--34, 111--148, 382--402                                                                 752--767, 19--24, 717--727, 280--281                               29%, (62--257/5-- 200, 205); 29%, (83--257/1-- 175, 181)                                                            (1--181)&                                       25--257                        NP_491008      alpha-CaTuliN (catenin/vinculin related) family member (ctn-1)
  **III**   4-A4           569     no      no                     164--338, 369--527;187--200, 206--222, 263--279, 305--321, 321--335, 506--527; 263--318, 388--452, 511--568   65--97, 19--38,112--139                                            32%, (154--567/18--397, 402)                                                                                        (334--542, 334--501)&; (1--569)\#               154--549                       NP_495753      associated with RAN (nuclear import/export) function family member (ran-3)
  **III**   25-H8          339     no      no                     24--84; 24--75                                                                                                215--276, 111--169, 187--201, 100--109                             41%, (22--75/7--61, 70)                                                                                             (1--152)&                                       1--99                          NP_495652      T09A5.8
  **III**   2-H9           356     no      no                     22--273; 1--108, 115--297; 13--284                                                                            192--215, 303--312, 338                                            42%, (1--284/1--289, 382)                                                                                           (1--335, 1--356) \$&                            1--197                         NP_497949      T23F11.1
  **III**   18-H1          208     no      no                     32--124; 36--113; 24--45, 51--68, 131--145, 164--181, 186--205                                                171--190, 114--171, 19--40                                         43%, (41--110/10-- 76, 90)                                                                                          (1--81)&\$                                      32--124                        NP_510410      HIStone family member (his-24)
  **III**   11049-D6       435     no      no                     293--433; 270--433                                                                                            110--152, 234--260, 175--186, 375--381                             no                                                                                                                  (1--156)\# ; (9--158, 1--119)\$&                261--435                       NP_001041025   Y41E3.7a
  **III**   9-G11          250     no      no                     1--194                                                                                                        228--232                                                           no                                                                                                                  (35--250)&                                      1--227                         NP_497076      R05H10.1
  **III**   10-E1          251     no      no                     no                                                                                                            158--199                                                           no                                                                                                                  (1--206)&                                       1--251                         NP_496943      W01G7.4
  **III**   37-F11         230     no      no                     1--230                                                                                                        106--126, 168--182                                                 no                                                                                                                  (45--179, 45--230)&                             1--230                         NP_507024      T10C6.5
  **III**   75-A8          228     no      no                     no                                                                                                            19--44, 125--135                                                   no                                                                                                                  (1--189)\$&                                     1--228                         NP_492509      F46A9.1
  **III**   11048-E2       262     no      no                     33--178; 61--179                                                                                              183--198                                                           no                                                                                                                  (1--262)\$                                      1--182                         NP_501337      MEChanosensory abnormality family member (mec-17)

\* column A: Prediction accuracy level (**I**, accurate; **II**, basically accurate; **III**, wrong) and Plate-ID, users could query/search the sequence relative information from the SGCE web site \[41\]; column B: number of amino acids in the ORF; column C: signal peptide prediction results using SignalP; column D: transmembrane region prediction results using TMHMM; column E: domains/fragments from Interpro/InterProScan analysis; column F: domain linker regions predicted by Domain Linker Finder; column G: PDB-alignment results, including the percentage of sequence identity, query/subject sequence start position and end position, and the length of the subject sequence; column H: experimental results from protein crystal/three-dimensional structures (labeled with \#), limited proteolysis (labeled with \$) or spontaneous degradation (labeled with &); column I: DDBP prediction results; J: Accession Number, user could obtain sequence relative information from National Center for Biotechnology Information (NCBI) \[40\]; K: Definition of the protein or ACEID for proteins without known functions.

\*\* 11020-H6 is corresponding to the region 299--792 of NP_493412.

Application of the DDBP method and the improved cloning strategy
----------------------------------------------------------------

We applied the DDBP method and the improved cloning strategy to see if the success rate for obtaining purified soluble recombinant proteins would be greatly improved when the predicted fragments were cloned for expressing recombinant proteins in *E. coli*. The test dataset includes 57 proteins from *C. elegans*ORFeome version 3.1, whose expression/purification data of ORFs using the same expression vector were available from previous experiments. For these 57 proteins, the coding regions corresponding to the DDBP predicted fragments were subjected to HTP cloning, and the expression/purification pipeline, in which 14 ones were shortened constructs.

Previously, all full-length proteins in this dataset, with the GATEWAY tags included at the N-terminus and the C-terminus, were treated as soluble by the 96-well expression profiling when expressed in *E. coli*. However, all but two proteins could not be purified from *E. coli*lysates prepared for expressing these proteins. Most of the recombinant proteins in this dataset were either unstable or formed large aggregates as shown by gel filtration chromatography. In contrast, after employing the DDBP method and improved cloning strategy that avoids GATEWAY encoded sequences, 50 proteins were expressed as soluble (Table [3](#T3){ref-type="table"}, Figure [6](#F6){ref-type="fig"}), and until now, at least 20 were successfully purified (Table [3](#T3){ref-type="table"}, Figure [7](#F7){ref-type="fig"}), among which four proteins had been crystallized (data not shown), despite that seven proteins were insoluble (Table [3](#T3){ref-type="table"}, Figure [6](#F6){ref-type="fig"}). There is a 10-fold increase in terms of obtaining purified proteins from this dataset, as shows the combination of DDBP method and our cloning strategy is successful and results in a clearly improved protein expression and purification. However we do not know whether the observed improvement mainly deprives from a correct domain prediction since most proteins in our testing set only have the shortened or the full length construct and the completely comparison cannot be done.

![**Soluble expression results of 57 proteins used for testing DDBP method**. ELISA results for soluble expression at 18°C and 37°C. Different shades in panels stand for different expression levels: the dark gray for the higher level, the gray for the medium level, the white for the lower level and the black for those not expressed, which was decided by comparisons with the positive control (A12 and B12, each containing one soluble protein). If ELISA readings of OD (optical density) at 405 nm was higher than or the same with the lower value of positive controls, the protein in this well was considered as expressed. Well C12 and D12 are negative controls and blank wells (white with no numbers) are null. After comparing the results at 18°C and 37°C, seven proteins (well B10, C10, E3, F3, G8, H3, and H9) were considered as not soluble.](1472-6750-7-45-6){#F6}

###### 

Constructs, soluble expression and purification results of 57 proteins used for testing DDBP method

  Well                                                                                                                               
  ------ ---- -------------- ---- ----- ----- ---------------------------------------------------------- ------------- ------------- -----
  A      2    NP_493355      1    300   300   C01A2.5                                                    medium        high          yes
  A      3    NP_001022737   1    264   264   X-box Binding Protein homolog family member (xbp-1)        medium        high          not
  A      7    NP_498947      1    282   282   PeRoXisome assembly factor family member (prx-19)          high          high          Yes
  A      9    NP_497226      1    253   253   W06E11.4                                                   medium        medium        not
  A      10   T26925         1    195   195   hypothetical protein Y45F10C.5                             medium        not soluble   not
  A      11   NP_495146      1    218   218   K05F1.9                                                    medium        high          not
  B      1    NP_495062      1    210   210   Helix Loop Helix family member (hlh-26)                    high          high          not
  B      2    NP_496422      1    225   225   B0491.3                                                    high          low           Yes
  B      3    NP_495475      1    197   240   F10E7.2                                                    not soluble   low           not
  B      4    NP_496547      21   284   284   W03C9.1                                                    medium        high          not
  B      5    NP_496156      29   184   184   R53.8                                                      low           high          not
  B      8    NP_501161      1    250   250   F42C5.3                                                    medium        high          Yes
  B      9    NP_502163      1    319   319   C10C6.3                                                    high          high          Yes
  B      10   NP_500772      55   348   368   ZK354.6                                                    not soluble   not soluble   not
  B      11   NP_501789      1    297   297   F25H8.1                                                    high          high          Yes
  C      1    NP_501895      1    294   294   R09E10.1                                                   medium        high          Yes
  C      2    NP_500890      1    243   243   H32C10.2                                                   high          high          not
  C      3    NP_501981      1    388   388   R102.5a                                                    low           low           not
  C      4    NP_507039      1    196   196   F14H3.5                                                    high          low           not
  C      5    NP_506094      1    183   183   F23H12.3                                                   medium        low           not
  C      6    NP_506094      1    90    183   F23H12.3                                                   not soluble   medium        Yes
  C      8    NP_505964      20   260   260   T04F3.2                                                    medium        medium        not
  C      9    NP_506495      1    252   252   D1086.4                                                    high          high          not
  C      10   NP_741113      1    394   419   C32A3.3a                                                   not soluble   not soluble   not
  C      11   NP_501199      1    299   299   F55G1.9                                                    not soluble   low           not
  D      1    NP_495021      1    197   197   EEED8.12                                                   high          high          not
  D      6    NP_502315      1    199   199   F35G2.2                                                    high          high          Yes
  D      10   NP_491869      1    232   232   MeDiaTor family member (mdt-18)                            medium        low           not
  E      1    NP_501936      1    190   190   F01D4.5b                                                   medium        low           not
  E      2    NP_506929      26   144   206   F57A10.4                                                   not soluble   low           not
  E      3    NP_506929      26   206   206   F57A10.4                                                   not soluble   not soluble   not
  E      5    NP_491210      1    249   249   T12F5.1                                                    high          high          not
  E      7    NP_506245      35   240   240   R186.3                                                     low           not soluble   not
  E      8    NP_495941      1    269   308   T24H10.1                                                   high          medium        Yes
  E      10   NP_510298      1    269   269   AMP-Activated Kinase Beta subunit family member (aakb-1)   medium        low           not
  F      1    NP_492285      1    239   239   F02E9.5                                                    medium        low           not
  F      2    NP_509787      1    195   195   F13E6.1                                                    medium        high          not
  F      3    AAZ82857       1    230   230   Hypothetical protein C17H12.13                             not soluble   not soluble   not
  F      4    NP_493382      1    210   210   Y87G2A.10                                                  high          medium        Yes
  F      5    NP_497990      1    214   214   C38D4.9                                                    high          high          Yes
  F      10   NP_498391      1    217   217   C56G2.15                                                   high          high          Yes
  G      2    NP_493230      1    183   183   W02A11.2                                                   high          not soluble   Yes
  G      3    NP_492005      1    189   189   F22D6.2                                                    high          high          Yes
  G      4    NP_492692      1    206   206   Y106G6E.4                                                  high          medium        Yes
  G      5    NP_492795      1    207   207   C34B2.5                                                    high          medium        Yes
  G      6    NP_491736      1    214   214   C06A5.2                                                    medium        high          not
  G      7    NP_491358      1    233   233   ZK973.9                                                    low           medium        not
  G      8    NP_492301      1    240   240   D1081.9                                                    not soluble   not soluble   not
  G      9    NP_492301      1    65    240   D1081.9                                                    high          high          Yes
  G      11   NP_491721      1    273   273   B0207.11                                                   high          high          not
  H      2    NP_491965      1    274   274   T21G5.4                                                    high          low           Yes
  H      3    NP_491348      1    287   287   Y47D9A.2a                                                  not soluble   not soluble   not
  H      4    NP_491903      27   330   363   D2092.4                                                    high          medium        not
  H      5    NP_496803      1    183   183   F15D4.2                                                    medium        low           not
  H      6    NP_491434      1    177   177   C10H11.7                                                   low           low           not
  H      8    NP_495527      30   179   179   F45E12.5b                                                  high          high          Yes
  H      9    NP_494315      1    276   276   F22E5.8                                                    not soluble   not soluble   not

![**Purification results of 57 proteins used for testing DDBP method**. Purification results for 15 of the 20 purified proteins. The name of each SDS-PAGE gel includes 2 parts, for example B2 (NP_496422), B2 corresponds to the well showed in Figure 6 and Table 3, and NP_496422 is the accession number of the protein in the public database \[40\]. The bands labeled with \'\'Cut\'\' in the figure correspond to the results after the cleavage by the thrombin and those labeled with \'\'Uncut\'\' correspond to the results before the cleavage. \'\'Aa\'\' in the figure stands for the amino acid range of the purified proteins.](1472-6750-7-45-7){#F7}

NP_506094 and NP_492301 are two only proteins with shortened and full length constructs in the test dataset. Notably, the shortened constructs of these two proteins are successfully expressed and purified, while their full length constructs are not soluble or cannot be purified. Though this result has no statistic meaning for DDBP method, it at least affirms that the DDBP is an effective method for some kinds of protein to find proper domain/fragment from the ORF for recombinant protein expression.

Conclusion
==========

In this paper we presented an effective HTP cloning pipeline and a domain/domain boundary prediction (DDBP) strategy. With this pipeline, four 96-well plates of genes could be cloned into an expression vector in seven days. After integrating the domain/domain boundary prediction strategy, the success rate of purification and crystallization was shown to increase dramatically. Moreover, this cloning pipeline, combined with our recombinant protein HTP expression pipeline and the crystal screening platform, constitutes a complete platform for structure genomics/proteomics. In the next stage, we will improve the accuracy of bioinformatics analysis of domain and domain boundaries and automates all bioinformatics procedures.

Methods
=======

Genes for HTP cloning
---------------------

A total of 90 genes from *C. elegans*ORFeome version 3.1 \[[@B5]\], 188 human genes from Human ORFeome versions 1.1 \[[@B6]\], and 88 genes from Brucella melitensis ORFeome version 1.1 \[[@B26]\] were used for evaluating the automated cloning modules. The cDNAs were provided by Dr. Vidal\'s group at Harvard Medical School as entry clones.

Datasets for domain/domain boundaries prediction
------------------------------------------------

Domain definition for 47 proteins was derived from experimental results and the dataset was used for validating the domain/domain boundary prediction scheme. Among them, some domains were defined by protein crystals/three-dimensional structures; some were defined by limited proteolysis or spontaneous degradation (Table [2](#T2){ref-type="table"}). The stable fragment from degraded samples was sequenced from the N-terminus and its molecular weight was determined by mass spectrometry. The domain definition was derived from the gene by starting at the N-terminus as sequenced and adding more amino acids in the gene sequence till the molecular weight matched that determined by mass spectrometry. This dataset was used to calibrate the domain/fragment prediction algorithm.

Another dataset that has no relevant experimental information for domain definition was also used to examine this prediction method. This dataset included 57 proteins from *C. elegans*ORFeome version 3.1. Full-length sequences in this dataset have been inserted into expression vectors previously for expressing recombinant proteins in *E. coli*with the GATEWAY tags (data not shown).

Bioinformatics tools
--------------------

BLAST \[[@B21]\] was used for alignments between our selected sequences and PDB \[[@B12]\] sequences. InterPro/InterProScan \[[@B19],[@B20],[@B36]\], was used to identify domain/fragment(s) of the ORF selected for generating a stable protein domain/fragment. Domain Linker Finder (DLF) \[[@B16],[@B37]\] was used for finding possible domain linker regions. SignalP \[[@B22],[@B23],[@B38]\] and TMHMM \[[@B24],[@B39]\] were used for prediction of the signal peptide and transmembrane (TM) regions. ExtractCDS, written in PERL, was developed as reported here and was used for extracting proper coding regions corresponding to selected domains. BatchPrimer, a comprehensive primer design program, was also developed here to carry out the batch primer design for the selected sequences.

Primer design and the PCR protocol for HTP cloning
--------------------------------------------------

We designed a PCR strategy of using two forward primers (F1, F2) and two backward primers (R1, R2) (Figure [1](#F1){ref-type="fig"}), modified from the strategy described by Kagawa and colleagues \[[@B34]\]. Primer F1 contains a part of the protease cleavage site followed by the gene specific sequence of 5\'-terminus: CCACGCGGCAGC- 5\'gene specific sequence. Primer R1 contains a part of the attB2 site followed by the gene specific sequence of the 3\'-terminal: CAAGAAAGCTGGGTTA-3\' gene specific sequence. Primer F2 contains the attB1 and the protease cleavage site: GGGGACAAGTTTGTACAAAAAAG CAGGCTTGGTGCCACGCGGCAGC, and R2 contains attB2 and the termination codon: GGGGACCACTTTGTACAAGAAAGCTGGGTTA. Gene specific regions in F1 and R1 are designed by BatchPrimer that would result in a pair of primers with a similar melting temperature (Tm) by adjusting the oligo length. The final Tm calculation was based on the formula of Breslauer and his colleagues \[[@B35]\], in which the salt concentration was set to 10 mM. The length of gene-specific oligos in the program was limited to between 20 to 30 bases according to our previous experimental results.

Different DNA polymerases and different protocols were investigated. After a number of tests, we selected AccuPrime™ Pfx (Invitrogen) as our final choice of DNA polymerase, and a corresponding multi-step laddered PCR protocol was devised as described in Figure [2](#F2){ref-type="fig"}. PCR starts with primers F1, F2 (F1:F2 = 1:10) and R1, R2 (R1:R2 = 1:10) \[[@B34]\] for 34 cycles. Amounts of oligos, templates and the polymerase are decided according to AccuPrime™ Pfx user manual.

![**A multi-step laddered PCR Protocol**. With this protocol, template DNA was amplified for 34 cycles with 5 minutes at 95°C for initial denaturation, 20 second at 94°C for denaturation, 30 second for annealing, 140 second at 68°C for extension and 10 minutes at 68°C for final extension. Annealing temperature was variable: it started from a relatively high temperature (55°C), and then decreased 1--2 degree each time until to 46°C. The temperature again increased 5 degree and stabilized at 51°C.](1472-6750-7-45-2){#F2}

Gateway cloning and small-scale protein expression
--------------------------------------------------

After running the batch PCR protocol, 96-well E-Gel (Invitrogen) was used to check PCR outcomes. Entry clones were generated with entry vector pDONR201 (Invitrogen) and the PCR products by the BP reaction. BP reaction and transformation of DH5α cells were performed according to the GATEWAY protocols from the manufacturer (Invitrogen). Mini-prep was carried out with QIAGEN 96-well mini-prep kits. Expression vectors were prepared in 96-well plates with the selected entry clones and vector pET15g \[[@B4]\], via the LR reaction. Expression vectors were plated, and single colonies were selected for mini-prep. All above procedures (Figure [3](#F3){ref-type="fig"}), except for colony picking, were automated in our integrated robotic pipeline, operating mainly on a BiomekFX robot, as previously described \[[@B4]\].

For protein expression, expression vectors were transformed into *E. coli*BL21(DE3)AI firstly. Then pick single colonies for recombinant protein expression. After overnight growth at 37°C, the bacteria were diluted (1:200) into 0.6 ml culture containing 100 μg/ml ampicillin in two 96-well block assay plates. After growing for 3--4 hours, without monitoring the absorbance of the culture, protein expression was induced at 18°C and 37°C by addition of IPTG to a final concentration of 1 mM. Protein expression was carried out for 3 hours at 37°C and 20 hours at 18°C.

Cell lysis and Enzyme-linked Immunosorbent Assay (ELISA)
--------------------------------------------------------

After protein expression, cells were spun down at 4000 rpm for 30 minutes and cell pellets were lysed by freezing overnight at -80°C and then thawed at room temperature for 15 minutes. Cell lysis was continued by shaking for 30 minutes at 1000 rpm in Vortemp shakers after the addition of 500 μl native lysis buffer (50 mM NaH~2~PO~4~, 300 mM NaCl, 10 mM imidazole, and 1 mg/ml lysozyme, pH 8.0). After lysis, plates were spun at 4000 rpm for 30 minutes and a Beckman Biomek FX robot was used to separate the supernatant, which contained only soluble proteins and was used for the solubility analysis of recombinant proteins by a dynamic indirect enzyme-linked immunosorbent assays (ELISA) protocol, from the pellet.

Indirect ELISAs were carried out on a Beckman/Sagian core system: an ORCA robotic arm (Beckman) for moving plates, a Biomek 2000 (Beckman) for handling liquid, a Biotek plate washer (Bio-Tex Instruments) for washing plates, and a SpectraMax plate reader (Molecular Devices) for recording and analyzing results. A mouse anti-His tag antibody (Anti-Penta-His, QIAGEN) was used as the primary antibody at a dilution of 1:500 and a rabbit anti-mouse IgG Fc alkaline phosphatase conjugate (Pierce) was used as the secondary antibody also at a dilution of 1:500. *p*-Nitrophenyl phosphate (ICN) was used to stain according to the manufacturer\'s instructions. After read absorbance at 405 nm for 6 hours, with an interval of 30 minutes, the results were electronically compiled and automatically scored with in-house software.

Large scale expression/purification of soluble proteins and thrombin cleavage of purified proteins
--------------------------------------------------------------------------------------------------

Based on results of ELISA, we performed large scale expression on the possible soluble proteins with same protocols as described above, except enlarging the culture volume from 0.6 ml to 6 liters and inducing cells when absorbance values at 595 nm reached 0.6 to 0.8. After the appropriate incubation (3 hours at 37°C or 20 hours at 18°C), cells were harvested by centrifugation (7000 rpm for 12 minutes). Cell pellets were then re-suspended in appropriate amount of binding buffer (for Ni-His6 affinity column, 20 mM Tris, 500 mM NaCl, 5 mM imidazole, and 0.01% NaAzide, pH 7.9) and completely lysed by sonicating. After centrifuge lysate for 30 minutes at 17000 rpm, remove the pellet and filter lysate through Watmann paper.

Collected proteins were firstly purified by use of the Ni-nitrilotriacetic acid agarose (Qiagen) affinity chromatography: the protein mixture was loaded to the column, and after washed the column, the proteins were eluted under native conditions (500 mM imidazole, 20 mM Tris, 500 mM NaCl, 0.01% NaAzide, pH7.9). Obtained proteins were then concentrated, and further purified by use of the standard protocols with ion-exchange (Hitrap Q column, Amersham) and size exclusion chromatography (superdex75 or superdex200 column, Amersham). Purified proteins will finally be treated with thrombin (Sigma).

For any purified proteins, before treatment with thrombin, a small amount of them were used for optimizing thrombin cutting concentrations: at room temperature, proteins were digested at a series of thrombin concentrations (0.1, 0.5, 1, and 5 unit per milligram of target protein) for 16 hours, and the concentration with the best result was chosen as the actual one. If digestion results were not good enough, try to increase or degrease the amount of thrombin and test again. Once the thrombin concentration was decided, the purified protein was mixed with proper amounts of thrombin and dialyzed in low salt buffer (20 mM Tris, 100 mM NaCl, pH7.5) at 4°C for 16 hours. Resulted proteins were checked by Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and used in crystallization trials.
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